QUESTIONS
Ipamorelin, Answered
The questions people actually ask — answered straight, and cited where the answer is a number.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that releases growth hormone by activating the ghrelin receptor. Its founding study showed it releases growth hormone potently in rats and pigs (pig half-maximal dose 2.3 nmol/kg) yet does not raise ACTH or cortisol — making it the first highly selective growth hormone secretagogue [1].
What does ipamorelin do for you?
In research terms, ipamorelin triggers a single pulse of the body's own growth hormone through the ghrelin receptor, without the cortisol or prolactin rise of older peptides [1]. It has no approved human use; its one efficacy trial, for gut recovery after surgery, did not beat placebo [3]. Reported community effects — better sleep, faster recovery — are anecdotal, not clinical findings.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic pentapeptide derived from the earlier peptide GHRP-1, with the development code NNC 26-0161 and molecular formula C38H49N9O5. It is a selective agonist of the ghrelin receptor (GHS-R1a), built with a non-natural amino acid and D-form residues for protease resistance, and is supplied as a freeze-dried powder for research [1].
How does CJC-1295 ipamorelin work?
The two work through different receptors. CJC-1295 is a GHRH analog (GHRH receptor); ipamorelin is a GHRP (ghrelin receptor). Because the pathways are independent, their growth-hormone effects add together, and GHRPs keep working even when glucose or somatostatin would blunt GHRH [11]. The combination has never been tested as a pair in a controlled human outcome trial [14].
Is ipamorelin selective for growth hormone?
Yes — that is its defining feature. In its founding characterisation, ipamorelin released growth hormone potently but did not raise ACTH or cortisol above the level seen with growth-hormone-releasing hormone, even at doses more than 200-fold above its growth-hormone threshold [1]. Prolactin stayed quiet too. That selectivity is what distinguishes it from older peptides like GHRP-6 and GHRP-2.
What are the risks of ipamorelin?
The honest answer leads with the unknowns: no Phase 3 trial, no long-term human safety data, and its one Phase 2 trial missed its endpoint [3]. A class-level concern is a 28-day rat study of a related ghrelin-receptor agonist that found dose-dependent heart-muscle degeneration [6]. Theoretical cautions involve the growth-hormone/IGF-1 axis and glucose control. Material quality from unregulated suppliers is also unverified.
Does ipamorelin reduce belly fat?
No human trial shows this. The most recent in-vivo study, in ferrets, found ipamorelin blunted chemotherapy-induced weight loss by about 24% — a weight-protecting effect, not fat loss in healthy subjects [5]. Community reports of a gradual leaner look are anecdotal and confounded by diet and training, not a measured clinical outcome.
What are the downsides of ipamorelin?
The biggest downside is the evidence gap: its only human efficacy trial failed to beat placebo [3], and there is no long-term human safety record. Reported adverse effects — facial flushing, tingling, mild water retention, increased appetite, injection-site irritation — are anecdotal and generally described as mild. A related compound showed cardiac toxicity in a 28-day rat study, underscoring the unknowns [6].
Why is ipamorelin being discontinued?
Ipamorelin was never an approved drug to discontinue. Its clinical development stopped because the only indication that reached Phase 2 — postoperative ileus — failed: the trial of 114 patients missed its primary endpoint [3]. With no efficacy demonstrated and no further trials, development simply did not continue. In 2024 the FDA also tightened compounding access by removing ipamorelin acetate from Category 2 of its interim 503A list.
What does CJC-1295 and ipamorelin do?
Together they aim to raise growth hormone through two routes at once — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor — which a class review shows produces synergistic, somatostatin-resistant release [11]. Each peptide's pharmacology is real, but the combination has not been validated for any clinical outcome in a controlled human trial [14]. Real-world effects are anecdotal.
Does ipamorelin increase IGF-1?
Not always, and not reliably in short studies. In the 15-day rat bone-growth study, ipamorelin raised bone growth dose-dependently yet produced no measurable change in total IGF-1 [4]. Sustained or combination protocols are more associated with IGF-1 elevation — an observational report of combined GHS therapy in men found raised IGF-1 [15] — but ipamorelin alone, short-term, often does not move it.
How much CJC-1295 ipamorelin should I take?
There is no validated human dose, and this site provides none. The CJC-1295 + ipamorelin combination has never been tested as a pair in a controlled human trial; its rationale is single-agent pharmacology only [14]. Community protocols are anecdotal and lack any peer-reviewed human dosing basis. Dosing decisions belong with a qualified clinician, not a website.
Does CJC-1295 ipamorelin work?
Each peptide has real, measured activity — ipamorelin reliably releases a growth-hormone pulse [1] and the GHRP class adds growth-hormone release on top of GHRH [11] — but the combination has not been validated for any clinical outcome in a controlled human trial [14]. Mechanistic plausibility is strong; outcome proof for the pair is absent. Reported results are anecdotal.
How to reconstitute CJC-1295 ipamorelin 5mg?
As a research material, ipamorelin is supplied freeze-dried and reconstituted with bacteriostatic water; it degrades with heat and freeze-thaw, so solution is typically refrigerated. These are general peptide-handling notes, not a preparation protocol for use in any person, and this site gives no concentrations or volumes for human use. Its human half-life is about two hours [2].
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life in humans is approximately two hours, with clearance of 0.078 L/h/kg [2]. Practically, that means blood levels fall by half roughly every two hours, and the growth-hormone pulse it triggers peaks near 40 minutes after dosing before subsiding [2]. It is a short-acting peptide, which is the pharmacologic reason it clears quickly.
Does ipamorelin make you hungry?
It can. Ipamorelin acts on the ghrelin receptor — the body's hunger-signal receptor — so increased appetite after dosing is a logical class-level effect and is occasionally reported in community accounts, generally described as milder than with GHRP-6. This is reported experience plus mechanism, not a measured clinical endpoint. It is one reason appetite-sensitive readers are listed among the cautions.
Will I gain weight on ipamorelin?
No human trial answers this. In a ferret model, ipamorelin protected against chemotherapy-induced weight loss [5], and the ghrelin-receptor mechanism can raise appetite. But ipamorelin's one human efficacy trial concerned gut recovery, not body weight, and missed its endpoint [3]. Any weight change in community use is anecdotal and confounded by diet, training, and concurrent compounds — not a measured outcome.
Does ipamorelin increase appetite?
Plausibly, through its mechanism. As a ghrelin-receptor agonist, ipamorelin engages the same receptor the hunger hormone uses, and increased appetite is a recognised class-level effect of ghrelin agonists, reported occasionally in community accounts and usually milder than with GHRP-6. No controlled human study has quantified ipamorelin's effect on appetite specifically; this is mechanism plus anecdote, not a clinical finding.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin receptor to release a single pulse of growth hormone, without raising cortisol or prolactin [1]. In animals it drives dose-dependent bone growth [4]; in humans it is well characterised pharmacokinetically [2] but unproven for efficacy [3]. It is a research chemical with no approved human use — and reported community benefits are anecdotal, not clinical.
How long does it take for ipamorelin to work?
Pharmacologically, fast. The growth-hormone pulse ipamorelin triggers peaks about 40 minutes (0.67 h) after dosing in human volunteers, then clears with a roughly two-hour half-life [2]. That is the measured acute response. Any longer-term subjective effects people describe — sleep, recovery — are anecdotal and appear over days to weeks in community accounts, not from controlled trials.
Does ipamorelin cause water retention?
Mild water retention is occasionally reported in community accounts, often in the first weeks and usually described as milder than with older peptides — but this is anecdotal, not a controlled-trial finding. Mechanistically, growth-hormone excess is associated with sodium and water retention, which makes the reports plausible; no ipamorelin trial has measured fluid balance at research-use exposures.
Where to inject CJC-1295 ipamorelin?
This site gives no administration instructions for any person. In research, ipamorelin has been studied by intravenous, subcutaneous, intranasal, and intraperitoneal routes [2]; subcutaneous is the dominant route in off-label community use but has no published human characterisation. Injection technique and site are clinical decisions outside this site's scope and belong with a qualified clinician — not a website.